Cell therapy for retinal disease.
Journal
Current opinion in ophthalmology
ISSN: 1531-7021
Titre abrégé: Curr Opin Ophthalmol
Pays: United States
ID NLM: 9011108
Informations de publication
Date de publication:
25 Jan 2024
25 Jan 2024
Historique:
medline:
26
1
2024
pubmed:
26
1
2024
entrez:
26
1
2024
Statut:
aheadofprint
Résumé
This review presents an update on completed stem cell therapy trials aimed at retinal diseases. In recent years, several clinical trials have been conducted examining the safety and role of cell therapy in diseases, including age-related macular degeneration, Stargardt's macular dystrophy, and retinitis pigmentosa. Studies have utilized a variety of cell lines, modes of delivery, and immunosuppressive regimens. The prevalence of fraudulent cell therapy clinics poses threats to patients. Clinical trials have begun to characterize the safety of cell therapy in retinal disease. While studies have described the potential benefits of cell therapy, larger studies powered to evaluate this efficacy are required to continue progressing toward preventing retinal disease. Nonapproved cell therapy clinics require regulation and patient education to avoid patient complications.
Identifiants
pubmed: 38276971
doi: 10.1097/ICU.0000000000001034
pii: 00055735-990000000-00149
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Zarbin M. Cell-based therapy for retinal disease: the new frontier. In: Weber BHF, Langmann T, editors. Retinal degeneration. Vol 1834. Methods in molecular biology. New York: Springer; 2019. pp. 367--381.
Hinkle JW, Mahmoudzadeh R, Kuriyan AE. Cell-based therapies for retinal diseases: a review of clinical trials and direct to consumer “cell therapy” clinics. Stem Cell Res Ther 2021; 12:538.
Kashani AH, Lebkowski JS, Rahhal FM, et al. One-year follow-up in a Phase 1/2a clinical trial of an allogeneic RPE cell bioengineered implant for advanced dry age-related macular degeneration. Trans Vis Sci Tech 2021; 10:13.
Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2015; 385:509–516.
Sung Y, Lee MJ, Choi J, et al. Long-term safety and tolerability of subretinal transplantation of embryonic stem cell-derived retinal pigment epithelium in Asian Stargardt disease patients. Br J Ophthalmol 2021; 105:829–837.
Heier JS, Ho AC, Samuel MA, et al. Safety and efficacy of subretinally administered palucorcel for geographic atrophy of age-related macular degeneration. Ophthalmol Retina 2020; 4:384–393.
Da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell–derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol 2018; 36:328–337.
Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell–derived retinal cells for macular degeneration. N Engl J Med 2017; 376:1038–1046.
Özmert E, Arslan U. Management of retinitis pigmentosa by Wharton's jelly-derived mesenchymal stem cells: prospective analysis of 1-year results. Stem Cell Res Ther 2020; 11:353.
Wiącek MP, Gosławski W, Grabowicz A, et al. Long-term effects of adjuvant intravitreal treatment with autologous bone marrow-derived lineage-negative cells in retinitis pigmentosa. Bourin P, ed. Stem Cells Int 2021; 2021:1–12.
Ho AC, Chang TS, Samuel M, et al. Experience with a subretinal cell-based therapy in patients with geographic atrophy secondary to age-related macular degeneration. Am J Ophthalmol 2017; 179:67–80.
Mehat MS, Sundaram V, Ripamonti C, et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. Ophthalmology 2018; 125:1765–1775.
Song WK, Park KM, Kim HJ, et al. Treatment of macular degeneration using embryonic stem cell-derived retinal pigment epithelium: preliminary results in Asian patients. Stem Cell Rep 2015; 4:860–872.
Li S, Liu Y, Wang L, et al. A phase I clinical trial of human embryonic stem cell-derived retinal pigment epithelial cells for early-stage Stargardt macular degeneration: 5-years’ follow-up. Cell Prolif 2021; 54:e13100.
Liu Y, Xu HW, Wang L, et al. Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration. Cell Discov 2018; 4:50.
Sugita S, Mandai M, Hirami Y, et al. HLA-matched allogeneic iPS cells-derived RPE transplantation for macular degeneration. JCM 2020; 9:2217.
Nirwan RS, Albini TA, Sridhar J, et al. Assessing “Cell Therapy” clinics offering treatments of ocular conditions using direct-to-consumer marketing websites in the United States. Ophthalmology 2019; 126:1350–1355.
Rong AJ, Lam BL, Ansari ZA, Albini TA. Vision loss secondary to autologous adipose stem cell injections: a rising problem. JAMA Ophthalmol 2018; 136:97–99.
Kuriyan AE, Albini TA, Townsend JH, et al. Vision loss after intravitreal injection of autologous “Stem Cells” for AMD. N Engl J Med 2017; 376:1047–1053.
Saraf SS, Cunningham MA, Kuriyan AE, et al. Bilateral retinal detachments after intravitreal injection of adipose-derived ‘Stem Cells’ in a patient with exudative macular degeneration. Ophthalmic Surg Lasers Imaging Retina 2017; 48:772–775.
Patel M, Holmes HR, Yannuzzi NA, et al. Patient understanding of nonapproved stem cell therapies for retinal disease. Ophthalmol Retina 2022; 6:254–255.